Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts
References (27)
- et al.
Propositions pour une tactique prophylactique des affections méningococciques
Médecine et Maladies Infectieuses
(1977) - et al.
Spread of meningococcal infection within households
Lancet
(1974) - et al.
Possibly avoidable deaths in hospital in the age-groups one week to two years
Lancet
(1976) - et al.
Le point sur la méningite cérébro-spinale
Le Concours Médical
(1976) - et al.
Les crèches et les prégardiennats en Belgique
Documents du Centre d'Etude de la Population et de la Famille
(1977) - et al.
Affections méningococciques en Belgique
- et al.
Consideration sur la chimioprophylaxie des meningococcies
Louvain Médical
(1977) - et al.
Meningococcal disease in Belgium, I. Risk of secondary cases among household contacts and evaluation of prophylaxis
Acta Paediatrica Belgica
(1978) - et al.
Etude statistique de 325 cas de méningites suppurées
Lyon Médical
(1972) - et al.
Epidemiology of sulfonamide-resistant meningococcal infections in a civilian population
American Journal of Epidemiology
(1971)
Epidemiological study of 383 cases of meningococcus meningitis in the city of Milwaukee, 1927–1928 and 1929
American Journal of Public Health
Space-time and family characteristics of meningococcal disease and Haemophilus meningitis
International Journal of Epidemiology
Septicemic meningococcus meningitis
Cited by (99)
Bacterial Meningitis
2023, Manson's Tropical Diseases, Fourth EditionLessons for and from the COVID-19 pandemic response — An appraisal of guidance for the public health management of Invasive Meningococcal Disease
2021, Journal of Infection and Public HealthCitation Excerpt :All of these guidelines specified an 8 -h minimum time and included any form of enclosed transport [15,23,24]. Only Australia defined a minimum time of contact for childcare settings (two full days or 20 cumulative hours in the same care group, based on a 1981 study on secondary case rates after IMD outbreaks in Belgian children [27]) [15]. Other guidelines left it to the discretion of the public health officer [20] whether to include childcare contacts as close contacts, or did not include childcare contacts at all [24,26].
Mass chemoprophylaxis for control of outbreaks of meningococcal disease
2018, The Lancet Infectious DiseasesCitation Excerpt :Vaccination might not be appropriate when the vaccine is not expected to help protect against the meningococcal outbreak strain, or when no vaccine is licensed or recommended for the affected age group. Antibiotic chemoprophylaxis is routinely recommended for close contacts of patients with meningococcal disease, who are estimated to have an up to 1600-fold increased risk of contracting meningococcal disease compared with the general population.6,7 The aim of chemoprophylaxis for intimate contacts is to eliminate colonisation with Neisseria meningitidis before the bacterium causes invasive disease or is transmitted to other contacts.
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
2016, VaccineCitation Excerpt :The clinical relevance of the MenC antibody kinetics induced by a 12 month MenCC vaccine following MenCC priming, or no priming, in infancy lies in the persistence of MenC rSBA GMTs above the protective threshold of ⩾8 which is important for sustained protection against invasive MenC disease. This is because the incubation period of meningococcal disease is short with the majority of secondary cases of IMD occurring 24 h to 7 days following exposure to an index case [19]. A rise in MenC rSBA titres to above the threshold of protection of ⩾8 only occurs around the 9th day following acquisition of MenC carriage in individuals with undetectable MenC bactericidal antibodies [20].
Neisseria meningitidis
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesBacterial Meningitis
2013, Manson's Tropical Diseases: Twenty-Third Edition